The long-acting dopamine agonist bromocriptine mesylate as additive immunosuppressive drug after kidney transplantation
Martin Clodi, A Luger(Universitat Autònoma de Barcelona), Gert Mayer(University of Vienna), Alice Schmidt, W Waldhäusl(University of Vienna), Golam Mustafa(University of Vienna), H. Kotzmann(University of Vienna), Ferdinand Mühlbacher(Vienna General Hospital), Ursula Barnas(University of Vienna), Walter H. Hörl(Medical University of Vienna), Michaela Riedl
Cited by 3
Related Papers
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
|New England Journal of Medicine|2010|574
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement
|Nephrology Dialysis Transplantation|2013|472
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450
Glucose Metabolism After Renal Transplantation
|Diabetes Care|2013|125